These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 27624080

  • 21. Grafted hyaluronic acid N-acetyl-l-methionine for targeting of LAT1 receptor: In-silico, synthesis and microscale thermophoresis studies.
    Waddad AY, Ramharack P, Soliman MES, Govender T.
    Int J Biol Macromol; 2019 Mar 15; 125():767-777. PubMed ID: 30553855
    [Abstract] [Full Text] [Related]

  • 22. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
    Montaser AB, Järvinen J, Löffler S, Huttunen J, Auriola S, Lehtonen M, Jalkanen A, Huttunen KM.
    ACS Chem Neurosci; 2020 Dec 16; 11(24):4301-4315. PubMed ID: 33228353
    [Abstract] [Full Text] [Related]

  • 23. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.
    Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H.
    Mol Pharmacol; 2002 Apr 16; 61(4):729-37. PubMed ID: 11901210
    [Abstract] [Full Text] [Related]

  • 24. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.
    Patel M, Dalvi P, Gokulgandhi M, Kesh S, Kohli T, Pal D, Mitra AK.
    Int J Pharm; 2013 Feb 25; 443(1-2):245-53. PubMed ID: 23270998
    [Abstract] [Full Text] [Related]

  • 25. The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.
    Venteicher B, Merklin K, Ngo HX, Chien HC, Hutchinson K, Campbell J, Way H, Griffith J, Alvarado C, Chandra S, Hill E, Schlessinger A, Thomas AA.
    ChemMedChem; 2021 Mar 03; 16(5):869-880. PubMed ID: 33230949
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan.
    Hall C, Wolfe H, Wells A, Chien HC, Colas C, Schlessinger A, Giacomini KM, Thomas AA.
    Bioorg Med Chem Lett; 2019 Aug 15; 29(16):2254-2258. PubMed ID: 31248771
    [Abstract] [Full Text] [Related]

  • 28. The Evaluation of l-Tryptophan Derivatives as Inhibitors of the l-Type Amino Acid Transporter LAT1 (SLC7A5).
    Graff J, Müller J, Sadurní A, Rubin M, Canivete Cuissa IA, Keller C, Hartmann M, Singer S, Gertsch J, Altmann KH.
    ChemMedChem; 2022 Sep 05; 17(17):e202200308. PubMed ID: 35895286
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation.
    Kärkkäinen J, Laitinen T, Markowicz-Piasecka M, Montaser A, Lehtonen M, Rautio J, Gynther M, Poso A, Huttunen KM.
    Bioorg Chem; 2021 Jul 05; 112():104921. PubMed ID: 33933805
    [Abstract] [Full Text] [Related]

  • 32. Large neutral amino acid transporter enables brain drug delivery via prodrugs.
    Gynther M, Laine K, Ropponen J, Leppänen J, Mannila A, Nevalainen T, Savolainen J, Järvinen T, Rautio J.
    J Med Chem; 2008 Feb 28; 51(4):932-6. PubMed ID: 18217702
    [Abstract] [Full Text] [Related]

  • 33. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
    Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, Kitashoji T, Ohgaki R, Tanaka H, Endou H, Endo K, Sakurai H, Kanai Y.
    J Nucl Med; 2012 Aug 28; 53(8):1253-61. PubMed ID: 22743251
    [Abstract] [Full Text] [Related]

  • 34. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
    Peura L, Malmioja K, Huttunen K, Leppänen J, Hämäläinen M, Forsberg MM, Gynther M, Rautio J, Laine K.
    Pharm Res; 2013 Oct 28; 30(10):2523-37. PubMed ID: 24137801
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.
    Hayashi K, Jutabha P, Maeda S, Supak Y, Ouchi M, Endou H, Fujita T, Chida M, Anzai N.
    J Pharmacol Sci; 2016 Nov 28; 132(3):201-204. PubMed ID: 27567475
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
    Huttunen J, Gynther M, Vellonen KS, Huttunen KM.
    Int J Pharm; 2019 Nov 25; 571():118714. PubMed ID: 31610281
    [Abstract] [Full Text] [Related]

  • 39. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
    Fukumoto S, Hanazono K, Fu DR, Endo Y, Kadosawa T, Iwano H, Uchide T.
    Biochem Biophys Res Commun; 2013 Sep 13; 439(1):103-8. PubMed ID: 23954667
    [Abstract] [Full Text] [Related]

  • 40. L-Type amino acid transporter 1 as a target for drug delivery.
    Puris E, Gynther M, Auriola S, Huttunen KM.
    Pharm Res; 2020 May 06; 37(5):88. PubMed ID: 32377929
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.